News & Updates

Gabapentin relieves paclitaxel-induced neuropathic pain

06 Feb 2025

The use of gabapentin is effective in reducing neuropathic pain due to paclitaxel chemotherapy, as shown in a study.

Gabapentin relieves paclitaxel-induced neuropathic pain

06 Feb 2025

SG’s first smartphone-based cancer prehab program sees early success

05 Feb 2025 by

A smartphone-based cancer prehabilitation program in Singapore is feasible and safe, with preliminary data showing high acceptability among local users.

SG’s first smartphone-based cancer prehab program sees early success

05 Feb 2025

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

04 Feb 2025

In patients with colorectal cancer, a history of allergy, previous oxaliplatin exposure, and chemotherapy regimens appear to increase the risk of having oxaliplatin hypersensitivity reactions, results of a recent study have shown.

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

04 Feb 2025

SG study underpins novel Tx strategies for OCCC

04 Feb 2025 by

A study from Singapore shows that targeted therapies such as bevacizumab, immune checkpoint inhibitors (ICIs), and secondary cytoreductive surgery (SCS) hold promise for the treatment of ovarian clear cell carcinoma (OCCC).

SG study underpins novel Tx strategies for OCCC

04 Feb 2025

Original New Drug Application Approvals by US FDA (16-31 January 2025)

04 Feb 2025

New drug applications approved by US FDA as of 16-31 January 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 January 2025)

04 Feb 2025

Add-on tiragolumab improves antitumour response in unresectable HCC

03 Feb 2025

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.

Add-on tiragolumab improves antitumour response in unresectable HCC

03 Feb 2025

Clozapine tied to haematological malignancy in schizophrenia

01 Feb 2025 by

The use of clozapine appears to slightly increase the risk of haematological malignancy (HM) among patients with schizophrenia compared with olanzapine use, suggests a study.

Clozapine tied to haematological malignancy in schizophrenia

01 Feb 2025

Laparoscopic noninferior to open surgery for low rectal cancer

01 Feb 2025

The disease-free survival outcome in patients with low rectal cancer who receive laparoscopic surgery compares favourably with that in those who receive open surgery, according to a study.

Laparoscopic noninferior to open surgery for low rectal cancer

01 Feb 2025

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025 by

A single tremelimumab regular interval durvalumab (STRIDE) provides survival benefits to Asian patients with unresectable hepatocellular carcinoma (HCC), as shown by the results of the HIMALAYA study.

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

28 Jan 2025

News & Updates

Filter by Specialty:

Specialty:

Gabapentin relieves paclitaxel-induced neuropathic pain

Gabapentin relieves paclitaxel-induced neuropathic pain

SG’s first smartphone-based cancer prehab program sees early success

SG’s first smartphone-based cancer prehab program sees early success

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

SG study underpins novel Tx strategies for OCCC

SG study underpins novel Tx strategies for OCCC

Original New Drug Application Approvals by US FDA (16-31 January 2025)

Original New Drug Application Approvals by US FDA (16-31 January 2025)

Add-on tiragolumab improves antitumour response in unresectable HCC

Add-on tiragolumab improves antitumour response in unresectable HCC

Clozapine tied to haematological malignancy in schizophrenia

Clozapine tied to haematological malignancy in schizophrenia

Laparoscopic noninferior to open surgery for low rectal cancer

Laparoscopic noninferior to open surgery for low rectal cancer

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC

Tremelimumab plus durvalumab improves survival in Asians with unresectable HCC